Unlock advanced strategies in cell therapy analytics

Seth Peterson is a seasoned professional in the field of pharma analytics. With a dedicated focus on supporting and advancing novel genomic methods. In his capacity at Thermo Fisher, Seth oversees application support initiatives, playing a crucial role in developing and implementing innovative genomic methods tailored for both research and regulated environments within the pharmaceutical industry. 

Dr. Kato Shum is an experienced and strategic Quality leader with over 12 years of experience across gene and cell therapy (i.e. RNA therapeutics, TIL cell therapy, allogenic and autologous CAR-T). Prior to his current role, Kato was Head of QC at CARGO Therapeutics, where he built the QC organization in both UK and US clinical manufacturing sites to advance the development of TIL therapy. Kato was previously Head of QC at Instil Bio, and he was also Associate Director of QC Technical Services at Kite Pharma, where he played an instrumental role in submission of both Yescarta® and Tecartus® BLAs as well as INDs of numerous investigational allogenic and autologous CAR-T products. In particular, he supported the QC method development, validation, transfer, product quality and oversight of external partners.

Anoop Chandran has over a decade of experience in the development of advanced immunotherapies with more than eight years focused on TCR based cell therapies. Anoop has led cross-functional teams responsible for analytical development and strategy across the product lifecycle. His work spans method development, validation, and lifecycle management for both T cell and viral vector products, including biological potency assays, with a strong emphasis on regulatory compliance and quality-by-design principles. He's contributed to IND, IMPD, and BLA submissions and has led initiatives in defining control strategies and assay development to support clinical and commercial manufacturing. 

Stephan O. Krause, PhD, is a biopharmaceutical quality and analytical science leader with over two decades of experience advancing global standards across biologics, cell therapies, and analytical control strategies. As Executive Director for Analytical Strategy at Bristol Myers Squibb, he leads analytical strategy development and lifecycle execution for cell therapy products across global sites. Stephan is the recipient of over a dozen publication and industry recognition awards and is known for his PDA leadership. He currently serves on several advisory boards and chairs several high-impact task forces, including PDA TR for Phase-Appropriate QMS for ATMPs and ANS-07 Analytical Standard Development.